We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

128 hedge funds and large institutions have $265M invested in Aratana Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 42 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 17

100% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 21

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

38% more capital invested

Capital invested by funds: $191M → $265M (+$73.5M)

28% more funds holding

Funds holding: 100128 (+28)

18% less call options, than puts

Call options by funds: $178K | Put options by funds: $218K

Holders
128
Holders Change
+28
Holders Change %
+28%
% of All Funds
3.42%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
45
Increased
42
Reduced
21
Closed
17
Calls
$178K
Puts
$218K
Net Calls
-$40K
Net Calls Change
-$138K
Name Holding Trade Value Shares
Change
Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$1.93M +$144K +17,370 +9%
WSA
27
Wall Street Associates
California
$1.85M +$1.64M +197,400 New
AllianceBernstein
28
AllianceBernstein
Tennessee
$1.84M +$1.3M +157,100 +401%
TC
29
TFS Capital
Pennsylvania
$1.8M +$1.48M +178,357 +1,231%
American Century Companies
30
American Century Companies
Missouri
$1.72M +$1.52M +183,617 New
EI
31
EAM Investors
California
$1.57M +$1.4M +168,075 New
Bank of New York Mellon
32
Bank of New York Mellon
New York
$1.28M +$3.63K +437 +0.3%
BIM
33
BlackRock Investment Management
Delaware
$1.23M +$48.9K +5,885 +5%
HHC
34
Hutchin Hill Capital
New York
$1.23M +$1.09M +131,000 New
CCMH
35
Cornerstone Capital Management Holdings
New York
$1.16M +$1.03M +124,093 New
Jacobs Levy Equity Management
36
Jacobs Levy Equity Management
New Jersey
$1.06M +$941K +113,300 New
NI
37
Numeric Investors
Massachusetts
$1.04M +$919K +110,646 New
Renaissance Technologies
38
Renaissance Technologies
New York
$1M -$1.13M -135,500 -56%
CCM
39
Cadence Capital Management
Massachusetts
$989K +$878K +105,675 New
KCM
40
Kornitzer Capital Management
Kansas
$964K -$576K -69,300 -40%
BCM
41
Bridgeway Capital Management
Texas
$814K
PP
42
PDT Partners
New York
$808K
Morgan Stanley
43
Morgan Stanley
New York
$760K +$618K +74,399 +1,087%
Goldman Sachs
44
Goldman Sachs
New York
$759K +$464K +55,830 +221%
Citadel Advisors
45
Citadel Advisors
Florida
$754K +$302K +36,348 +82%
Asset Management One
46
Asset Management One
Japan
$747K +$663K +79,803 New
Charles Schwab
47
Charles Schwab
California
$682K +$161K +19,400 +36%
GA
48
Geneva Advisors
Illinois
$665K +$9.38K +1,130 +2%
California State Teachers Retirement System (CalSTRS)
49
California State Teachers Retirement System (CalSTRS)
California
$661K +$5.81K +700 +1%
DTL
50
Dynamic Technology Lab
Singapore
$641K +$569K +68,515 New

PETX Hedge Fund Activity: Q3 2016 in Review

128 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2016, worth a combined $265M — up 38% from $191M a quarter earlier.

Buyers outnumbered sellers: 45 funds opened new PETX positions and 17 closed out — a net gain of 28 holders — while 42 added to existing stakes and 21 trimmed.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $9.99M. The largest seller was Jennison Associates, cutting an estimated $13.6M.

  • 128 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2016, up from 100 in Q2 2016.
  • Funds reported $265M of Aratana Therapeutics, Inc. stock for Q3 2016, up 38% quarter-over-quarter.
  • 45 funds opened new Aratana Therapeutics, Inc. positions in Q3 2016 and 17 closed out, a net change of +28 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q3 2016 was Acadian Asset Management, an estimated $9.99M added.
  • The largest Aratana Therapeutics, Inc. seller in Q3 2016 was Jennison Associates, an estimated $13.6M sold.

Based on aggregated 13F filings for Q3 2016.